Presidio Medical this week closed $30 million in financing for its neuromodulation platform technology.
The company’s technology is designed to provide pain relief to various pain types where conventional treatment has failed.
Presidio Medical said the investment will be used to develop the technology further to treat chronic pain and expand applications of the platform to address other unmet indications.
The financing round was led by Invus Opportunities and Action Potential Venture Capital.